[1]Padhani AR, Koh DM, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions[J]. Radiology, 2011, 261(3): 700-718.
[2]Morani AC, Elsayes KM, Liu PS, et al. Abdominal applications of diffusion-weighted magnetic resonance imaging: where do we stand[J]. World J Radiol, 2013, 5(3): 68-80.
[3]Boeker M, Franca F, Bronsert P, et al. TNM-O: ontology support for staging of malignant tumours[J]. J Biomed Semantics, 2016, 7(1): 64.
[4]Surov A, Stumpp P, Meyer HJ, et al. Simultaneous (18)F-FDG-PET/MRI: associations between diffusion, glucose metabolism and histopathological parameters in patients with head and neck squamous cell carcinoma[J]. Oral Oncol, 2016, 58: 14-20.
[5]Rasmussen JH, Norgaard M, Hansen AE, et al. Feasibility of multiparametric imaging with PET/MR in head and neck squamous cell carcinoma[J]. J Nucl Med, 2017, 58(1): 69-74.
[6]Ohba Y, Nomori H, Mori T, et al. Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F18 in imaging non-small cell lung cancer?[J]. J Thorac Cardiovasc Surg, 2009, 138(2): 439-445.
[7]Regier M, Derlin T, Schwarz D, et al. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer(NSCLC): does the apparent diffusion coefficient(ADC) correlate with tracer uptake(SUV)?[J]. Eur J Radiol, 2012, 81(10): 2913-2918.
[8]Schmidt H, Brendle C, Schraml C, et al. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system[J]. Invest Radiol, 2013, 48(5): 247-255.
[9]Zhang S, Xin J, Guo Q, et al. Comparison of tumor volume between PET and MRI in cervical cancer with hybrid PET/MR[J]. Int J Gynecol Cancer, 2014, 24(4): 744-750.
[10]Sun H, Xin J, Zhang S, et al. Anatomical and functional volume concordance between FDG PET, and T2 and diffusion-weighted MRI for cervical cancer: a hybrid PET/MR study[J]. Eur J Nucl Med Mol Imaging, 2014, 41(5): 898-905.
[11]Shih IL, Yen RF, Chen CA, et al. Standardized uptake value and apparent diffusion coefficient of endometrial cancer evaluated with integrated whole-body PET/MR: correlation with pathological prognostic factors[J]. J Magn Reson Imaging, 2015, 42(6): 1723-1732.
[12]Kong E, Chun KA, Bae YK, et al. Integrated PET/MR mammography for quantitative analysis and correlation to prognostic factors of invasive ductal carcinoma[J]. Q J Nucl Med Mol Imaging, 2018, 62(1): 118-126.
[13]Karan B, Pourbagher A, Torun N. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors[J]. J Magn Reson Imaging, 2016, 43(6): 1434-1444.
[14]Cerny M, Dunet V, Prior JO, et al. Initial staging of locally advanced rectal cancer and regional lymph nodes: comparison of diffusion-weighted MRI with 18F-FDG-PET/CT[J]. Clin Nucl Med, 2016, 41(4): 289-295.
[15]Tomizawa M, Shinozaki F, Uchida Y, et al. Diffusion-weighted whole-body imaging with background body signal suppression/T2 image fusion and positron emission tomography/computed tomography of upper gastrointestinal cancers[J]. Abdom Imaging, 2015, 40(8): 3012-3019.
[16]Usuda K, Sagawa M, Maeda S, et al. Diagnostic performance of whole-body diffusion-weighted imaging compared to PET-CT plus brain MRI in staging clinically resectable lung cancer[J]. Asian Pac J Cancer Prev, 2016, 17(6): 2775-2780.
[17]Schaarschmidt BM, Buchbender C, Nensa F, et al. Correlation of the apparent diffusion coefficient(ADC) with the standardized uptake value(SUV) in lymph node metastases of non-small cell lung cancer(NSCLC) patients using hybrid 18F-FDG PET/MRI[J]. PLoS One, 2015, 10(3): e0122545.
[18]Usuda K, Maeda S, Motono N, et al. Diagnostic performance of diffusion-weighted imaging for multiple hilar and mediastinal lymph nodes with FDG accumulation[J]. Asian Pac J Cancer Prev, 2015, 16(15): 6401-6406.
[19]Choi EK, Kim JK, Choi HJ, et al. Node-by-node correlation between MR and PET/CT in patients with uterine cervical cancer: diffusion-weighted imaging versus size-based criteria on T2WI[J]. Eur Radiol, 2009, 19(8): 2024-2032.
[20]Miccò M, Vargas HA, Burger IA, et al. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer[J]. Eur J Radiol, 2014, 83(7): 1169-1176.
[21]Ergul N, Kadioglu H, Yildiz S, et al. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy[J]. Acta Radiol, 2015, 56(8): 917-923.
[22]Ono K, Ochiai R, Yoshida T, et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography(FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases[J]. J Magn Reson Imaging, 2009, 29(2): 336-340.
[23]Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment—utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT[J]. Radiology, 2008, 248(2): 643-654.
[24]Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging(DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy[J]. J Magn Reson Imaging, 2009, 30(2): 298-308.
[25]Lee SM, Goo JM, Park CM, et al. Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT[J]. Eur Radiol, 2016, 26(11): 3850-3857.
[26]Granata V, Fusco R, Catalano O, et al. Early assessment of colorectal cancer patients with liver metastases treated with antiangiogenic drugs: the role of intravoxel incoherent motion in diffusion-weighted imaging[J]. PLoS One, 2015, 10(11): e0142876.
[27]Lee DH, Lee JM, Hur BY, et al. Colorectal cancer liver metastases: diagnostic performance and prognostic value of PET/MR imaging[J]. Radiology, 2016, 280(3): 782-792.
[28]Ippolito D, Fior D, Trattenero C, et al. Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer[J]. World J Radiol, 2015, 7(12): 509-520.
[29]Giraudo C, Raderer M, Karanikas G, et al. 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance in lymphoma: comparison with 18F-fluorodeoxyglucose positron emission tomography/computed tomography and with the addition of magnetic resonance diffusion-weighted imaging[J]. Invest Radiol, 2016, 51(3): 163-169.
[30]Mosavi F, Wassberg C, Selling J, et al. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes[J]. Clin Radiol, 2015, 70(11): 1229-1236.
[31]Ohno Y, Koyama H, Yoshikawa T, et al. Three-way comparison of whole-body MR, coregistered whole-body FDG PET/MR, and integrated whole-body FDG PET/CT imaging: TNM and stage assessment capability for non-small cell lung cancer patients[J]. Radiology, 2015, 275(3): 849-861.
[32]Regacini R, Puchnick A, Shigueoka DC, et al. Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies[J]. Sao Paulo Med J, 2015, 133(2): 141-150.
[33]Derlin T, Bannas P. Imaging of multiple myeloma: current concepts[J]. World J Orthop, 2014, 5(3): 272-282.
[34]Basu S, Chryssikos T, Moghadam-Kia S, et al. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities[J]. Semin Nucl Med, 2009, 39(1): 36-51.
[35]Kumar Y, Khaleel M, Boothe E, et al. Role of diffusion weighted imaging in musculoskeletal infections: current perspectives[J]. Eur Radiol, 2017, 27(1): 414-423.
[36]Kogan F, Fan AP, McWalter EJ, et al. PET/MRI of metabolic activity in osteoarthritis: a feasibility study[J]. J Magn Reson Imaging, 2017, 45(6): 1736-1745.
[37]AlSabban Z, Church P, Moineddin R, et al. Accuracy and interobserver agreement of diffusion-weighted imaging in pediatric inflammatory bowel disease[J]. Clin Imaging, 2017, 41: 14-22.
[38]Stanescu-Siegmund N, et al. Quantification of inflammatory activity in patients with Crohn’s disease using diffusion weighted imaging(DWI) in MR enteroclysis and MR enterography[J]. Acta Radiol, 2017, 58(3): 264-271.
[39]Catalano OA, Gee MS, Nicolai E, et al. Evaluation of quantitative PET/MR enterography biomarkers for discrimination of inflammatory strictures from fibrotic strictures in Crohn disease[J]. Radiology, 2016, 278(3): 792-800.
[40]Prato FS, Butler J, Sykes J, et al. Can the inflammatory response be evaluated using 18F-FDG within zones of microvascular obstruction after myocardial infarction?[J]. J Nucl Med, 2015, 56(2): 299-304.
[41]Gong J, Cao W, Zhang Z, et al. Diagnostic efficacy of whole-body diffusion-weighted imaging in the detection of tumour recurrence and metastasis by comparison with 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography or computed tomography in patients with gastrointestinal cancer[J]. Gastroenterol Rep(Oxf), 2015, 3(2): 128-135.
[42]Varoquaux A, Rager O, Dulguerov P, et al. Diffusion-weighted and PET/MR imaging after radiation therapy for malignant head and neck tumors[J]. Radiographics, 2015, 35(5): 1502-1527.
[43]Soderlund AT, Chaal J, Tjio G, et al. Beyond 18F-FDG: characterization of PET/CT and PET/MR scanners for a comprehensive set of positron emitters of growing application—18F, 11C, 89Zr, 124I, 68Ga, and 90Y[J]. J Nucl Med, 2015, 56(8): 1285-1291.
[44]Lai CH, Lin G, Yen TC, et al. Molecular imaging in the management of gynecologic malignancies[J]. Gynecol Oncol, 2014, 135(1): 156-162.